Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill shows promise for Tough-to-Treat bladder cancer

NCT ID NCT04917809

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a pill called erdafitinib in 20 people whose non-muscle invasive bladder cancer has returned after standard treatments like BCG. All participants have a specific change in the FGFR3 gene, which the drug targets. They take the pill for about a month before their scheduled surgery to see if it shrinks or eliminates the tumor.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Erdafitinib (a pill that blocks the FGFR3 protein)
What this could lead to
If successful, this could point toward a new targeted treatment option for people with recurrent bladder cancer that has a specific genetic change (FGFR3 mutation).
What could go wrong
This is a very small, early-phase trial with only 20 participants. It tests a short treatment window before standard surgery, so it is not designed to prove long-term benefit or cure. The drug may cause side effects like high phosphate levels.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-invasive bladder urothelial carcinoma Non-Muscle Invasive Bladder Neoplasms urinary bladder cancer urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER FGFR3 GENE MUTATION RECURRENT BLADDER CANCER

Contacts and locations

Locations

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Commack (Limited Protocol Activities)

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau (Limited Protocol Activities)

    Uniondale, New York, 11553, United States

  • Memorial Sloan Kettering Westchester (Limited Protocol Activities)

    Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.